Entera Bio (ENTX)
(Delayed Data from NSDQ)
$1.71 USD
0.00 (0.00%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.71 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.71 USD
0.00 (0.00%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.71 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth D Momentum D VGM
Zacks News
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy
by Zacks Equity Research
Entera Bio (ENTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
by Zacks Equity Research
AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.
Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Entera Bio Ltd. (ENTX) and PetIQ (PETQ) have performed compared to their sector so far this year.
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
by Zacks Equity Research
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
by Zacks Equity Research
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
by Zacks Equity Research
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
by Zacks Equity Research
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
by Zacks Equity Research
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
by Zacks Equity Research
Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.
Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
by Zacks Equity Research
Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
by Zacks Equity Research
The FDA removes the partial clinical hold on Larimar's (LRMR) nomlabofusp clinical program for the treatment of patients with Friedreich's Ataxia.
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
by Zacks Equity Research
GSK's depemokimab has the potential to become the first ultra-long-acting biologic for severe asthma with a six-month dosing schedule
Sanofi (SNY) Signs Deal for AI-Powered Drug Development
by Zacks Equity Research
Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.
J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
by Zacks Equity Research
Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.
Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
by Zacks Equity Research
Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.
Are Medical Stocks Lagging Entera Bio (ENTX) This Year?
by Zacks Equity Research
Here is how Entera Bio Ltd. (ENTX) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Intellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company provides developmental and regulatory updates on its pipeline candidates. Stock rises.
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Ironwood (IRWD) incurs loss in the first quarter of 2024. Revenues decline year over year and miss estimates. The company lowers revenue guidance for 2024. Stock falls.
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
by Zacks Equity Research
Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Mirum's (MIRM) earnings and revenues miss estimates in the first quarter of 2024. Livmarli drives year-over-year sales.
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
by Zacks Equity Research
Beam Therapeutics (BEAM) reports mixed first-quarter results. The company remains focused on pipeline development.
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
by Zacks Equity Research
Here is how Arbutus Biopharma (ABUS) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.
Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
The latest trading day saw Entera Bio Ltd. (ENTX) settling at $1.98, representing a -1% change from its previous close.
Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
by Zacks Equity Research
In the closing of the recent trading day, Entera Bio Ltd. (ENTX) stood at $2.24, denoting a +0.9% change from the preceding trading day.